Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
60
GALDY Quote, Financials, Valuation and Earnings
Last price:
$40.73
Seasonality move
:
1.67%
Day range:
$40.56 - $41.45
52-week range:
$17.27 - $42.93
Dividend yield:
0.04%
P/E ratio:
130.29x
P/S ratio:
10.52x
P/B ratio:
4.98x
Volume:
32.2K
Avg. volume:
314.7K
1-year change:
84.63%
Market cap:
$48.7B
Revenue:
$4.4B
EPS (TTM):
$0.32
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Galderma Group AG has -- downside to fair value with a price target of -- per share.
GALDY vs. S&P 500
-
Over the past 5 trading days, Galderma Group AG has overperformed the S&P 500 by 0.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Galderma Group AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Galderma Group AG has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Galderma Group AG reported revenues of --.
Earnings Growth
-
Galderma Group AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Galderma Group AG reported earnings per share of --.
Enterprise value:
40.7B
EV / Invested capital:
--
Price / LTM sales:
10.52x
EV / EBIT:
58.11x
EV / Revenue:
8.69x
PEG ratio (5yr expected):
--
EV / Free cash flow:
55.57x
Price / Operating cash flow:
66.85x
Enterprise value / EBITDA:
40.33x
Gross Profit (TTM):
$3.2B
Return On Assets:
2.98%
Net Income Margin (TTM):
8.12%
Return On Equity:
4.9%
Return On Invested Capital:
3.62%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-01-02 | 2025-01-02 | 2025-01-02 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $1.8B | $1.9B | |
| Total Assets | -- | -- | -- | $12.6B | $12.9B | |
| Current Liabilities | -- | -- | -- | $1.5B | $1.8B | |
| Total Liabilities | -- | -- | -- | $4.9B | $5.1B | |
| Total Equity | -- | -- | -- | $7.6B | $7.7B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-01-02 | 2025-01-02 | 2025-01-02 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
GALDY
Sector
Market Cap
$48.7B
$28.1M
Price % of 52-Week High
96.55%
50%
Dividend Yield
0.04%
0%
Shareholder Yield
0.96%
-1.54%
1-Year Price Total Return
84.63%
-17.67%
Beta (5-Year)
--
0.503
Dividend yield:
0.04%
Annualized payout:
$0.00
Payout ratio:
-10.89%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$41.57
200-day SMA
Buy
Level
$31.50
Bollinger Bands (100)
Buy
Level
34.22 - 39.66
Chaikin Money Flow
Buy
Level
2.6M
20-day SMA
Buy
Level
$41.41
Relative Strength Index (RSI14)
Buy
Level
57.17
ADX Line
Buy
Level
29.54
Williams %R
Neutral
Level
-59.7372
50-day SMA
Buy
Level
$38.86
MACD (12, 26)
Buy
Level
0.75
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
1.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.491)
Buy
CA Score
(Annual)
Level (0.0177)
Buy
Beneish M-Score
(Annual)
Level (-2.2961)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.9728)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Stock Forecast FAQ
In the current month, GALDY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GALDY average analyst price target in the past 3 months is --.
-
Where Will Galderma Group AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Galderma Group AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Galderma Group AG?
Analysts are divided on their view about Galderma Group AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Galderma Group AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Galderma Group AG's Price Target?
The price target for Galderma Group AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GALDY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Galderma Group AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GALDY?
You can purchase shares of Galderma Group AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Galderma Group AG shares.
-
What Is The Galderma Group AG Share Price Today?
Galderma Group AG was last trading at $40.73 per share. This represents the most recent stock quote for Galderma Group AG. Yesterday, Galderma Group AG closed at $41.45 per share.
-
How To Buy Galderma Group AG Stock Online?
In order to purchase Galderma Group AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GALDY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GALDY
Sector
P/E ratio
130.29x
23.88x
PEG ratio
--
-0.01x
P/B ratio
4.98x
1.82x
Price / LTM sales
10.52x
1.59x
Growth Metrics
GALDY
Sector
Revenue growth
--
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
--
6.46%
Earnings forecast
--
-$0.18
Profitability
GALDY
Sector
Profitability FY 2024
$3.1B
$3.6M
Return on invested capital
3.62%
-31.77%
Return on assets
2.98%
-28.18%
Return on equity
4.9%
-37.47%
Earnings Date
Last Earnings Date
Jul
24
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Oct
23
Balance Sheet
GALDY
Sector
Total cash
$458M
$26.3M
Short term investments
--
$26M
Total assets
$12.6B
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.92% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 2.76% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 8.14% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
